To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06253650
Title Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)
Acronym TRINITY
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.